Clinical Report: Transanal Endoscopic Sphincter-Sparing Resection for Low Rectal Neoplasms
Overview
This study evaluates the feasibility, safety, and clinical efficacy of Transanal Endoscopic Sphincter-Preserving Resection (TA-ESPR) in patients with low rectal tumors. The findings indicate a 100% en bloc and complete resection rate with a low recurrence rate of 2.7%.
Background
Transanal Endoscopic Sphincter-Preserving Resection (TA-ESPR) is a novel technique aimed at treating low rectal tumors while preserving anal function. Traditional surgical options often lead to significant complications, including permanent stoma formation and fecal incontinence, which can severely impact patients' quality of life. As the issue of overtreatment becomes more apparent, TA-ESPR offers a minimally invasive alternative for patients who decline radical surgery.
Data Highlights
Parameter
Value
Patients Enrolled
37
Low-Grade Rectal Cancer
73%
Neuroendocrine Tumors
16.2%
Stromal Tumors
10.8%
En Bloc Resection Rate
100%
Complete Resection Rate
100%
Recurrence Rate
2.7%
Mean Follow-Up Duration (months)
36.86 ± 16.71
Key Findings
TA-ESPR achieved a 100% en bloc resection rate.
Complete resection rate was also 100% among the patients studied.
The mean follow-up duration was 36.86 months.
The recurrence rate post-TA-ESPR was 2.7%.
No severe adverse events were reported during the study.
73% of patients had low-grade rectal cancer.
Clinical Implications
TA-ESPR presents a safe and effective treatment option for patients with low rectal tumors, particularly for those with significant comorbidities or those who refuse radical surgery. The technique not only preserves anal function but also enhances postoperative quality of life.
Conclusion
TA-ESPR is a promising ultra-minimally invasive approach for managing low rectal tumors, demonstrating high efficacy and safety in preserving anal function.
